159 related articles for article (PubMed ID: 19200830)
1. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.
Salleras L; Navas E; Domínguez A; Ibáñez D; Prat A; Garrido P; Asenjo MA; Torner N
Vaccine; 2009 May; 27(25-26):3454-8. PubMed ID: 19200830
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P
Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.
Salleras L; Domínguez A; Pumarola T; Prat A; Marcos MA; Garrido P; Artigas R; Bau A; Brotons J; Bruna X; Català P; Carreras E; Cuadra D; Gatell A; Millet S; Oller J; Raga E
Vaccine; 2006 Nov; 24(44-46):6638-42. PubMed ID: 16842892
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years.
Esposito S; Marchisio P; Bosis S; Lambertini L; Claut L; Faelli N; Bianchi C; Colombo GL; Principi N
Vaccine; 2006 Jan; 24(5):629-35. PubMed ID: 16157429
[TBL] [Abstract][Full Text] [Related]
6. Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.
Herzog C; Hartmann K; Künzi V; Kürsteiner O; Mischler R; Lazar H; Glück R
Vaccine; 2009 Jul; 27(33):4381-7. PubMed ID: 19450630
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of influenza vaccination of healthy children.
Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
9. [Assessment of efficacy and economic impact of an influenza vaccination campaign in the personnel of a health care setting].
Cella MT; Corona G; Tuccillo E; Franco G
Med Lav; 2005; 96(6):483-9. PubMed ID: 16983973
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of annual influenza vaccination of children.
Meltzer MI; Neuzil KM; Griffin MR; Fukuda K
Vaccine; 2005 Jan; 23(8):1004-14. PubMed ID: 15620473
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
12. Safe vaccination of children with a virosomal adjuvanted influenza vaccine.
Künzi V; Dornseiff M; Horwath J; Hartmann K
Vaccine; 2009 Feb; 27(8):1261-5. PubMed ID: 19114080
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness of influenza vaccination The Netherlands].
Reinders A; Postma MJ; Govaert TM; Sprenger MJ
Ned Tijdschr Geneeskd; 1997 Jan; 141(2):93-7. PubMed ID: 9036354
[TBL] [Abstract][Full Text] [Related]
14. Utility of virosomal adjuvated influenza vaccines: a review of the literature.
Gasparini R; Lai P
J Prev Med Hyg; 2010 Mar; 51(1):1-6. PubMed ID: 20853669
[TBL] [Abstract][Full Text] [Related]
15. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy.
Esposito S; Gasparini C; Martelli A; Zenga A; Tremolati E; Varin E; Marseglia GL; Fiocchi A; Principi N
Vaccine; 2008 Aug; 26(36):4664-8. PubMed ID: 18639601
[TBL] [Abstract][Full Text] [Related]
16. Economic benefits of inactivated influenza vaccines in the prevention of seasonal influenza in children.
Salleras L; Navas E; Torner N; Prat AA; Garrido P; Soldevila N; Domínguez A
Hum Vaccin Immunother; 2013 Mar; 9(3):707-11. PubMed ID: 23295894
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545
[TBL] [Abstract][Full Text] [Related]
18. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada.
Skowronski DM; Woolcott JC; Tweed SA; Brunham RC; Marra F
Vaccine; 2006 May; 24(19):4222-32. PubMed ID: 16423432
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients.
Evison J; Farese S; Seitz M; Uehlinger DE; Furrer H; Mühlemann K
Clin Infect Dis; 2009 May; 48(10):1402-12. PubMed ID: 19361304
[TBL] [Abstract][Full Text] [Related]
20. [Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance].
Hak E; Knol LM; Wilschut JC; Postma MJ
Ned Tijdschr Geneeskd; 2010; 154():A1188. PubMed ID: 20977784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
